Emma Walmsley, GlaxoSmithKline CEO (Credit: Fang Zhe/Xinhua/Alamy Live News)

The fire un­der Glax­o­SmithK­line's Em­ma Walm­s­ley grows as an­oth­er well-known ac­tivist in­vestor grabs its pitch­fork — re­port

Blue­bell Cap­i­tal Part­ners, a proxy brawler fresh off a cam­paign to oust glob­al food gi­ant Danone’s CEO and most of its board of di­rec­tors, has bought a stake in UK drug­mak­er Glax­o­SmithK­line with its eyes trained di­rect­ly on Em­ma Walm­s­ley, the Fi­nan­cial Times re­port­ed Wednes­day.

The Lon­don-based hedge fund joins an­oth­er no­to­ri­ous ac­tivist firm in Paul Singer’s El­liott Man­age­ment, which ear­li­er this year called for a shake­up in lead­er­ship at GSK to han­dle what the com­pa­ny de­scribed as a wealth of rich­es across the drug gi­ant’s port­fo­lio hin­dered by lim­it­ed vi­sion from top staff.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.